And Japanese pharma Eisai said the FDA will undertake an accelerated review of a new indication for its acid reflux drug Aciphex. ...
The statements follow news at the weekend that US regulators have granted priority review for Eisai's Aciphex acid reflux drug to also be used in patients ...
all 5 news articles
ACIPHEX was discovered and developed by Eisai and is copromoted in the United States with PriCara(R), a Division of Ortho-McNeil-Janssen Pharmaceuticals, ...
T: Quote, Profile, Research) Aciphex acid reflux drug, Japan's fourth-largest drug maker said. A priority review means the Food and Drug Administration ...
The statements follow news at the weekend that US regulators have granted priority review for Eisai's Aciphex acid reflux drug to also be used in patients ...
The FDA will review the use of Aciphex for short-term treatments of up to 8 weeks for gastroesophageal reflux disease in patients aged 12 to 16, ...
The delay is frustrating Eisai President Haruo Naito's attempts to develop successors to Aciphex and Aricept, the company's best-selling treatment for ...
Viagra 4. Aciphex 5. Ambien CR 6. Levitra 7. Lamisil 8. Lunesta 9. Wellbutrin XL 10. Ortho Evra Source: ePharma Consumer(R) v7.0, Manhattan Research, LLC.
... Vfend® (voriconazole), AcipHex® (rabeprazole), Nexium® (esomeprazole), Prevacid® (lansoprazole), Prilosec® (omeprazole), Protonix® (pantoprazole), ...